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Abstract
Background: There are limited data comparing the performance of the two commercially available interferon gamma (IFN-
c) release assays (IGRAs) for the diagnosis of tuberculosis (TB) in children. We compared QuantiFERON-TB gold In Tube (QFT-
IT), T-SPOT.TB and the tuberculin skin test (TST) in children at risk for latent TB infection or TB disease.
Methodsand Findings:The resultsof bothIGRAs werecomparedwithdiagnosisassignedbyTST-basedcriteria andassessedin
relation to TB contact history. Results from the TST and at least one assay were available for 96 of 100 children. Agreement
between QFT-IT and T-SPOT.TB was high (93% agreement, k=0.83). QFT-IT and T-SPOT.TB tests were positive in 8 (89%) and 9
(100%) children with suspected active TB disease. There was moderate agreement between TST and either QFT-IT (75%,
k=0.50)orT-SPOT.TB(75%,k=0.51).Among38children withTST-definedlatentTBinfection,QFT-ITgoldandT-SPOT.TBassays
were positive in 47% and 39% respectively. Three TST-negative children were positive by at least one IGRA. Children with a TB
contact were more likely than children without a TB contact to have a positive IGRA (QFT-IT LR 3.9; T-SPOT.TB LR 3.9) and a
positive TST (LR 1.4). Multivariate linear regression analysis showed that the magnitude of both TST induration and IGRA IFN-c
responses was significantly influenced by TB contact history, but only the TST was influenced by age.
Conclusions: Although a high level of agreement between the IGRAs was observed, they are commonly discordant with the
TST. The correct interpretation of a negative assay in a child with a positive skin test in clinical practice remains challenging
and highlights the need for longitudinal studies to determine the negative predictive value of IGRAs.
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Introduction
The detection and treatment of latent tuberculosis (TB)
infection is a key strategy in the control of TB [1,2]. Improved
methods for detecting both latent TB infection and TB disease in
children are needed. Interferon gamma release assays (IGRAs)
incorporating Mycobacterium tuberculosis (MTB)-specific antigens
have emerged as potential replacements for the century old
tuberculin skin test (TST) [3]. IGRAs have been shown to have
high sensitivity and specificity in adults [4] but there are few
studies that have assessed their performance for the diagnosis of
latent TB infection or TB disease specifically in children [5]. A
recent meta-analysis highlighted an urgent need for more evidence
for the use of IGRAs for the diagnosis of latent TB infection in
children [6]. The aim of this study was to compare the
performance of two commercial IGRAs with TST in the diagnosis
of children at risk for latent TB infection or with suspected active
TB disease at a tertiary paediatric hospital.
Methods
Patients and inclusion criteria
The study was approved by the Human Research and Ethics
Committee of the Royal Children’s Hospital Melbourne. Patients
were recruited prospectively from the hospital’s TB, refugee health
and infectious diseases clinics. Children at risk of latent TB infection
orwithsuspectedactiveTBdisease wereeligiblefor inclusion.At risk
was defined as a recent TB contact and/or recent immigration from
a country with a high prevalence of TB. Written informed consent
was obtained from parents or participants in their preferred
language. Demographic and clinical details were obtained from
eachpatient by a detailed questionnaire, including: country and date
of birth; TB exposure history; Bacille Calmette-Gue ´rin (BCG)
vaccination history; presence of BCG scar and symptoms suggestive
of TB. All patients had a full clinical evaluation, a TST and blood
tests including IGRA, full blood count and CD4 lymphocyte count.
HIV tests were not done as part of this study.
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A Mantoux test was performed by intradermal injection of 10
international units tuberculin (Purified Protein Derivative (PPD)
100 IU/mL, CSL, Melbourne, Australia), the standard dose of
tuberculin PPD used inAustralia at the time ofthe study, by trained
personnel and read after 48 to 72 hours. An assessment of the level
of risk for TB infection was taken into consideration when defining
the result of the TST, as recommended by recently modified local
guidelines (Victorian Department of Human Services). A positive
TST was defined as $10 mm in patients with moderate risk factors
(origin from high prevalence country; age 1 to 5 years); and
$5 mm in patients with high risk factors (household TB contact;
age less than 1 year). If BCG was given within five years prior to the
TST, the TST was considered positive if induration was $15 mm
in moderate risk patients and $10 mm in high risk patients. In
children with suspected active TB disease, TST induration $5m m
was considered positive. Victorian guidelines for TST interpreta-
tion are similar to those of the American Thoracic Society (ATS),
except that the potential influence of prior BCG is taken into
consideration. Chest radiography was undertaken in those with a
positive TST or when clinically indicated, and reported by
radiologists who were blinded to the results of the IGRAs for each
patient. Children deemed to have latent TB infection were offered
isoniazid preventive treatment.
Interferon gamma release assays
A whole blood assay, QuantiFERON-TB gold In-Tube (QFT-
IT), Cellestis Ltd, Australia and an enzyme-linked immunospot
assay (ELISPOT), T-SPOT.TB, Oxford Immunotec, Oxford, UK
were carried out according to the manufacturers’ guidelines and
defined as positive, negative or indeterminate based on manufac-
turers’ recommended criteria. The laboratory scientists undertak-
ing the IGRAs were blinded to the clinical status of the patients.
The QFT-IT (3
rd generation) assay incorporates an additional
MTB-specific antigen TB 7.7 in addition to ESAT-6 and CFP-10.
This assay was undertaken at the Victorian Infectious Disease
Reference Laboratory Melbourne (VIDRL). The T-SPOT.TB test
was undertaken in the Microbiology Research Laboratory at the
Royal Children’s Hospital Melbourne. Spots were counted with a
magnifying glass and expressed as spots per million peripheral
blood mononuclear cells (PBMC). Two further independent
observers, also blinded to clinical status allocation, confirmed spot
counts and assigned results.
Definitions
Latent TB infection was defined as an asymptomatic child with a
positive TST and chest radiograph not suggestive of TB. Active TB
disease was defined as a child with a positive TST with symptoms
suggestive of TB and/or an abnormal chest radiograph consistent
with TB, or a child with MTB cultured from clinical specimens.
Symptoms considered suggestive of TB included the following:
cough for more than two weeks, persistent fever, night sweats and
weight loss. Uninfected was defined as a well child with a negative
TST or a child with symptoms potentially suggestive of TB but in
whom results of all investigations for TB were negative or a child
with an alternative diagnosis and complete recovery in the absence
of specific TB treatment.
Statistics
Data were analysed using Prism Graphpad (Version 5).
Nonparametric unpaired data (TST indurations) were analysed
by the Mann-Whitney U test. The mean age of children was
compared using an unpaired t test or one-way anova. A Fisher’s
exact or chi-square test was used to compare proportions when the
results of IGRAs were analysed as dichomatous outcomes, and an
unpaired t test was used when IGRA antigen responses were
analysed as continuous measures. Agreement between TST and
IGRAs was assessed by the kappa statistic [7]. A multivariate
linear regression model was used to determine the influence of age,
BCG scar, origin from country with high TB prevalence and TB
contact on the results of TST and IGRAs. Correlations were
assessed using the Spearman’s correlation coefficient.
Results
Clinical and demographic details are shown in Table 1. Of 101
children enrolled in the study, four (4%) failed to return for a TST
Table 1. Demographic, clinical and laboratory details of study
participants.
Latent TB TB disease Uninfected
(n=38) (n=9) (n=49)
Demographic
Mean age in years (range) 10.2 (0.7–18.8) 8.2 (1.8–13.6) 8.4 (0.5–19.0)
Male 17 (45%) 5 (55%) 28 (57%)
Born in high TB prevalence
area
30 (79%) 8 (89%) 43 (88%)
TB contact
Household 16 (42%) 8 (89%) 10 (20%)
Non-household 6 (16%) 1 (11%) 1 (2%)
No known contact 16 (42%) 0 38 (78%)
Clinical
TB symptoms 1 (3%)
* 6 (67%) 3 (6%)
BCG
Scar present 23 (61%) 1 (11%) 21 (43%)
History but no scar 2 (5%) 1 (11%) 2 (4%)






0–4 mm 0 0 40 (82%)
5–9 mm 3 (8%) 1 (11%) 8 (16%)
10–14 mm 12 (32%) 0 1 (2%)
$15 mm 23 (60%) 7 (78%) 0
Induration median (range) 15 (8–37) 21 (6–24) 0 (0–10)
Chest radiograph
Normal 35 (92%) 1 (11%)
{ 19 (39%)
Abnormal 2 (5%)
1 8 (89%) 1 (2%)
|
Not done/unavailable 1 (3%)
** 0 29 (59%)
Laboratory
CD4 median (IQR)
{{ 40% (38–52%) 43% (30–56%) 40% (35–52%)
*Final diagnosis Klebsiella pneumoniae pneumonia; cough.2 weeks; sputum
samples AFB negative.
{One child with TB disease did not have a TST.
{Extrapulmonary TB.
1One child with evidence of prior TB; one child with right upper lobe
opacification (K. pneumoniae on culture).
|Right upper lobe opacification (culture negative).
**Well, asymptomatic child; failed to attend for follow up CXR.
{{CD4 count available for 82 children.
doi:10.1371/journal.pone.0002624.t001
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criteria. Mycobacterium gordanae was cultured from the sputum of one
child, who was subsequently excluded from further analysis. Of the
remaining 96 children, 82 (85%) originated from a high TB
prevalence country. On the basis of pre-defined criteria for
categorising patients to diagnostic groups, 38 (40%) children had
latent TB infection, 9 (9%) TB disease and 49 (51%) were
uninfected. The mean age of the children in the three groups was
not significantly different (p=0.19). No child had a clinical
presentation consistent with HIV infection and all children had a
CD4% within the normal range for age.
The agreement between observers for the T-SPOT.TB assay
results was high (interobserver reliability 96%). In four tests there
was a discrepancy in assigning a result (one observer positive, two
observers negative in each instance) with all four finally deemed
negative by consensus. Although there were more indeterminate
results with the T-SPOT.TB assay than with the QFT-IT assay
overall (14/96 vs. 3/96, p=0.009), the majority of indeterminate
results for the T-SPOT.TB assay were attributable to potential
laboratory error (Tables 2 and 3). Specifically, of the 14
indeterminate T-SPOT.TB assays, inadequate PBMC separation
accounted for seven and cross-contamination occurred in two
assays. Excluding these nine assays, the difference in the
proportion of ‘true’ indeterminate results between the two assays
was not statistically significant (3/96 vs. 5/87, p=0.48).
The proportion of indeterminate results for both IGRA was
higher in children younger than three years of age compared to
those older than three years of age. Specifically, of 16 children
younger than three years of age, two (12.5%) had an indeterminate
QFT-IT assay result (one inadequate mitogen control, one high nil
control) compared to one (1.1%) indeterminate result (inadequate
mitogen control) in the 84 children older than three years of age
(p=0.06). Similarly, of the 16 children younger than three years of
age, five (31.3%) had an indeterminate T.SPOT.TB assay result
(four inadequate PBMC, one technical) compared to nine (10.7%)
indeterminate results (three high nil control, two inadequate
PBMC, two technical, two cross contamination) in the 84 children
older than three years of age (p=0.05).
When the assays both yielded interpretable (ie non-indeterminate)
results, the overall agreement between QFT-IT and T-SPOT.TB
was high (93% agreement, k=0.83, 95% CI 0.65–0.91). However,
the results between the two IGRAs were discordant in six children
(Table 3). Results were QFT-IT positive / T-SPOT.TB negative in
four children (two with household TB contact and positive TST of
Table 2. Results of QuantiFERON-TB gold in-Tube and T-SPOT.TB assays in each diagnostic category.
QuantiFERON-TB gold In-Tube T-SPOT.TB
Positive Negative Indeterminate Positive Negative Indeterminate
All patients (n=100) Latent TB (n=38) 18 (47%) 20 (53%) (0) 15 (39%) 19 (50%) 4 (10%)
*
TB disease (n=9) 8 (89%) 1 (11%) 0 9 (100%) 0 0
Uninfected (n=49) 2 (4%) 44 (90%) 3 (6%)
{ 1 (2%) 38 (78%) 10 (20%)
{
No TST result (n=4) 1 (25%) 3 (75%) 0 0 4 (100%) 0
Patients with TB contact (n=44) Latent TB (n=22) 13 (59%) 9 (41%) 0 10 (46%) 10 (46%) 2 (9%)
1
TB disease (n=9) 8 (89%) 1 (11%) 0 9 (100%) 0 0
Uninfected (n=11) 1 (9%) 8 (73%) 2 (18%)
| 1 (9%) 5 (45%) 5 (45%)
**
No TST result (n=2) 1 (50%) 1 (50%) 0 0 2 (100%) 0
*3 inadequate PBMC; 1 cross contamination.
{1 high nil control; 2 inadequate mitogen control.
{3 high nil control; 4 inadequate PBMC; 2 technical; 1 cross contamination.
11 inadequate PBMC; 1 cross contamination.
|1 inadequate mitogen control; 1 high nil control.
**3 inadequate PBMC; 1 technical; 1 high nil control.
doi:10.1371/journal.pone.0002624.t002
Table 3. Comparison of the results of QuantiFERON-TB gold in-Tube and T-SPOT.TB assays.
QuantiFERON-TB gold In-Tube
Positive Negative Indeterminate
T-SPOT.TB All patients (n=100)* Positive 22 (22%) 2 (2%) 1 (1%)
Negative 4 (4%)* 56 (55%)* 1 (1%)
Indeterminate 3 (3%) 10 (10%) 1 (1%)
Patients with latent TB infection (n=38) Positive 14 (37%) 1 (3%) 0
Negative 2 (5%) 17 (45%) 0
Indeterminate 2 (5%) 2 (5%) 0
*Includes children where TST result was unavailable.
k (95% CI) for agreement between T-SPOT.TB and QuantiFERON-TB gold In-Tube in all patients was 0.83 (0.65–0.91) and in patients with latent TB infection was 0.82
(0.54–0.92).
doi:10.1371/journal.pone.0002624.t003
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one uninfected; one with a household TB contact in whom a TST
result was unavailable). Results were QFT-IT negative / T-
SPOT.TB positive in two children (one with household TB contact
andapositiveTSTof25 mm,categorisedaslatentTBinfection;one
with TB disease and a positive TST (22 mm)).
There was only moderate agreement between TST and QFT-
IT (75%, k=0.50, 95% CI 0.34–0.56) and between TST and T-
SPOT.TB (75%, k=0.51, 95% CI 0.35–0.55) overall (Figure 1).
The QFT-IT assay was positive in 18 (47%) and the T-SPOT.TB
assay was positive in 15 (39%) of the 38 children with TST-defined
latent TB infection (Table 2). Combining results from both IGRAs
detected only one additional patient with TST-defined latent TB
infection compared to QFT-IT alone, increasing the detection rate
to 19/38 (50%). The results of both IGRAs were negative in 17
(45%) of the 38 children with TST-defined latent TB infection.
Seven of these children had a TST induration $15 mm and eight
had a TB contact (Table 4).
Three (6.1%) of the 49 children with a negative TST categorised
as uninfected by study criteria were positive by at least one IGRA.
These comprised a 9-year old (QFT-IT positive / T-SPOT.TB
indeterminate (high nil control)) with no prior BCG immunisation,
who was a household TB contact; a BCG-immunised 15-year old
(QFT-IT positive / T-SPOT.TB negative) from a high TB
prevalence country with no known TB contact; and a 2-year old
(QFT-IT indeterminate / T-SPOT.TB positive) with no prior BCG
immunisation, who was a household TB contact. Of the children
with TB disease, results of the QFT-IT and T-SPOT.TB tests were
positive in 8 (89%) and 9 (100%) children respectively.
The responses to the MTB-specific antigens for both IGRAs are
showninFigure 2.In the T-SPOT.TBassay,the mean(SEM) IFN-c
response to ESAT-6 and CFP-10 was higher in children with TB
disease compared to those with latent TB infection (ESAT-6 396
(125.7) vs. 173.3 (51.1) spot forming cells per million PBMC (SFC/
10
6), p=0.07; CFP-10 421.3 (146.2) vs. 136.5 (35.6) SFC/10
6,
p=0.007).SimilarlytheIFN-cresponsetoESAT-6and CFP-10was
higher in children with latent TB infection compared to uninfected
children (ESAT-6 173.3 (51.1) vs. 14.7 (10.4) SFCs/10
6, p=0.001;
CFP-10 136.5 (35.6) vs. 10.4 (5.6) SFCs/10
6,p = 0 . 0 0 0 4 ) .I nt h e
QFT-IT assay mean (SEM) IFN-c responses to ESAT-6, CFP-10
and TB 7.7 were alsosignificantly higher inchildren with TB disease
comparedtothosewithlatentTBinfection(12.44 (1.9)vs.4.65(1.06)
IU/ml, p=0.002). Similarly, children with latent TB infection had
significantly higher mean IFN-c responses than uninfected children
(4.65 (1.06) vs. 0.06 (0.03) IU/ml, p,0.0001).
The influenceofage,BCGscar,originfromcountrywithhigh TB
prevalence and TB contact on the results of TST and IGRAs was
assessed. There was no significant difference in the median TST
induration between BCG-immunised and BCG-non-immunised
children overall or within the subgroup of children with latent TB
infection(allchildrenwithTST.0 mm(n=55):13 mmvs.17 mm;
p=0.25; children with latent TB infection (n=38): 15 mm vs.
17 mm;p=0.47).Amongthe87childrenwithlatentTBinfectionor
who were uninfected, the mean age of those with a positive or
negative QFT-IT (10.3 vs 9.2 years, p=0.4) or T-SPOT.TB (10.3 vs
9.5 years, p=0.54) assay was similar. Children with a TB contact
were more likely than those without a TB contact to have a positive
TST, a positive QFT-IT and a positive T-SPOT.TB (Table 5).
In a multivariate linear regression analysis, age (p=0.03) and
TB contact (p,0.0001), but not BCG scar (p=0.86) or origin
from a country with high TB prevalence (p=0.30), were
significantly correlated with the magnitude of TST induration.
In contrast, the only factor that significantly influenced the
magnitude of the IFN-c response in the IGRAs was TB contact
(QFT-IT and T.SPOT.TB, p,0.0001). The proportion of
children with a TB contact who had a positive TST (at both a
5 mm and a 10 mm cut-off) was higher than the proportion with a
Figure 1. Venn diagram depicting agreement between tuber-
culin skin test, QuantiFERON-TB gold In Tube and T-SPOT.TB
results for all children (n=100).
doi:10.1371/journal.pone.0002624.g001
Table 4. Details of the results from children with latent TB infection and negative QuantiFERON-TB gold in tube or T.SPOT.TB
results.
IGRA result TST induration (mm)
$5t o9 $10 to 14 $15
QFT-IT T-SPOT.TB No. of children (No. non BCG immunised)
All patients with latent TB infection (n=22) Negative (1 positive) 3 (2) 7 (2) 10 (3)
(2 positive) Negative 3 (2) 9 (2) 7 (3)
Both negative 3 (2) 7 (2) 7 (3)
Either negative 3 (2) 9 (2) 10 (3)
Patients with latent TB infection and TB contact (n=11) Both negative 3 (2) 2 (2) 3 (1)
Either negative 3 (2) 4 (2) 4 (1)
doi:10.1371/journal.pone.0002624.t004
Immune Assay and TB and Child
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setting (Table 5). In contrast, the IGRAs appeared to be more
specific (with respect to TB contact) than the TST.
Discussion
This is the largest study to date to compare the two currently
available commercial IGRAs with TST for the diagnosis of latent
TB infection specifically in children. The level of agreement
between QFT-IT and T-SPOT.TB in our study (k=0.83) was
higher than that observed in the studies by Arend et al (k=0.59)
[8] and Leyten et al [9] (k=0.71). The infrequent occurrence of
discordant results between the IGRAs suggests that either assay
can be used depending on resources and availability. However,
there was significant discordance between the results of TST and
both IGRAs. This is important because IGRAs are increasingly
considered potential replacements for TST for the detection of
latent TB infection [10,11]. Specifically, of 38 children with TST-
defined latent TB infection, less than half had a positive QFT-IT
or T-SPOT.TB. A critical question, with important implications
for the future use and interpretation of IGRAs, is whether this is
the result of false positive TST or false negative IGRA results [12].
Several studies have questioned the sensitivity of IGRAs
[8,13,14,15,16,17,18,19,20]. We previously found poor agreement
between QFT-TB Gold (an earlier 2
nd generation QuantiFERON
assay) and TST (k=0.3) for the diagnosis of latent TB infection [14].
In our previous study, a high proportion of children with a household
TB contact positive by TST were negative by QFT-TB Gold and the
assay was negative in almost half of the children with a TST
.15 mm. Compared with our previous study, we found better
agreement between TST and both QFT-IT and T-SPOT.TB
although it is not clear whether this is clinically significant. For the
QFT-IT assay, better agreement may be explained by the
incorporation of an additional MTB-specific antigen (TB 7.7)
conferring increased sensitivity [18]. However, the sensitivity of
I G R A sf o rt h ed e t e c t i o no fl a t e n tT Bi n f e c t i o ni nc h i l d r e nr e m a i n s
questionable with our finding that in children with TST indurations
$15 mm who had latent TB infection, only 13/23 (57%) QFT-IT
Figure 2. Results of T-SPOT.TB (panels A and B) and QuantiFERON-TB gold In Tube assays (panel C) according to tuberculin skin
test-based diagnosis. The dotted line depicts the test cut-off value for a positive test.
doi:10.1371/journal.pone.0002624.g002
Table 5. The influence of TB contact on TST, QFT-IT and T-SPOT.TB results for the 87 children with latent TB infection (n=38) or





without TB contact LR (95% CI)
Yes No
TST (cut off $5 mm) Pos 22 25 22/33 (67%) 29/54 (54%) 1.4 (0.98–2.0)
Neg 11 29
TST (cut off $10 mm) Pos 19 17 19/33 (58%) 37/54 (68%) 1.8 (1.1–2.8)
Neg 14 37
TST (cut off $15 mm Pos 13 10 13/33 (39%) 44/54 (81%) 2.1 (1.0–4.2)
Neg 20 44
QFT-IT Pos 14 6 14/31 (45%) 47/53 (89%) 3.9 (1.8–9.2)
Neg 17 47
T-SPOT.TB Pos 11 5 11/26 (42%) 42/47 (89%) 3.9 (1.6–10.0)
Neg 15 42
doi:10.1371/journal.pone.0002624.t005
Immune Assay and TB and Child
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Furthermore, in the 22 children with TST-defined latent TB
infection with either a negative QFT-IT or a negative T-SPOT.TB
result, almost a third had a TB contact and almost half had a TST
$15 mm and, importantly, discordant results occurred even in the
absence of BCG vaccination. Of note, there were three children
(including one without prior BCGvaccination) with a TB contact and
TST $15 mm in whom the results of both IGRAs were negative.
Our results are consistent with a recent large TB contact
investigation in non-BCG vaccinated adults in which the QFT-IT
and T-SPOT.TB assays were positive in only 42% and 51%
respectively of those with a TST induration $15 mm [8].
Similarly, in another recent study, less than half of immigrants
with a TST induration $15 mm were positive by QFT-TB Gold
and the overall agreement between TST and QFT-TB Gold was
poor (k=0.37) [21]. Another study in adults showed poor
agreement between QFT-IT, an ELISPOT assay and a 6 day
lymphocyte-stimulation assay [9]. Of 27 TST positive adults
(mean induration 16 mm), 9 (33%) and 11 (46%) individuals tested
positive by QFT-IT and ELISPOT respectively. One explanation
for these results as well as the findings in our study is that
discordant results are due to superior sensitivity of TST for the
detection of latent TB infection revealing ‘false negative’ IGRA.
However, the finding of three children in our study (two with a
household TB contact) with a negative TST and at least one
positive IGRA appears to be inconsistent with this explanation.
The alternate explanation for discordant TST and IGRA results
is that IGRA have superior specificity and reveal ‘false positive’
TST results [22,23,24]. The lack of a gold standard for latent TB
infection is a recognised inherent limitation of all studies that
investigate the use of IGRAs for the detection of latent TB
infection. Therefore estimating the sensitivity of any new test for
latent TB infection is problematic. In the absence of a recognised
gold standard, analysis of results with respect to TB contact history
is one way to infer potential superiority of one test over another for
the detection of latent TB infection. Although it is recognised that
not all individuals exposed to a smear positive TB contact will
subsequently become infected, this has become an accepted ‘gold
standard’ on which to base comparative evaluations. Our finding
that IGRAs have higher specificity than TST at any cut off with
respect to TB contact history is consistent with the possibility that
IGRAs have superior specificity for the detection of children with
‘true’ latent TB infection.
There are at least four further potential explanations for
discordance between TST and IGRAs results. Firstly, in contrast
to the TST which remains positive for a protracted period after past
or cleared MTB infection [8,25] recent evidence suggests that QFT-
IT and T-SPOT.TB assays detect more recent or ongoing infection
[26,27]. This may be because the IGRAs predominantly detect
effector MTB-specific T cells in an overnight stimulation assay
whereas TST induration is measured at 48–72 hours allowing for
the expansion ofmemoryT cellpopulations [8,13].Interestingly a 6-
day lymphocyte-stimulation test correlated better with TST than
overnight IGRA in one study [9]. Secondly, IGRAs may revert to
negative following clearance of TB infection [28]. Thirdly, prior
sensitisation by non-tuberculosis mycobacteria, which is common in
highTBprevalencecountries,couldleadtofalsepositiveTSTresults
in some patients. In a recent study, 24% of children with non-
tuberculosis mycobacteria had TST indurations .15 mm [29] and
TST indurations .20 mm have been reported in this setting [30].
Lastly, the dose of the tuberculin PPD used in skin test reagents
worldwide is not standardised. Though unlikely, the standard use of
10 IU of tuberculin PPD in Australia at the time of the study
potentially resulted in more ‘false positive’ TST results.
The correct interpretation of a negative IGRA in a patient with
a positive TST in routine clinical practice is challenging,
particularly if the patient has a documented TB contact. In the
absence of definitive evidence to confirm that discordant results
are attributable to false positive TST results, our current practice is
to offer isoniazid preventive treatment irrespective of IGRA result.
However, a recent Japanese high school TB contact investigation
provides preliminary evidence for withholding preventive treat-
ment in individuals with TST positive / IGRA negative results
[31]. Of 349 students in this study, 95 had a positive TST (defined
as erythema $30 mm in those with prior BCG and contact with
smear positive index case) of whom only four had a positive QFT-
TB Gold assay result. Preventive treatment was offered to these
four only, significantly reducing the number of students in whom
chemoprophylaxis was prescribed. Importantly, no student has
subsequently developed TB disease during a three and a half year
follow up. However, this study had a relatively short follow up and
does not address the issue of discordant results in young children in
whom the risk of progression to TB disease may be higher. Also,
until recently, it was not uncommon for individuals in Japan to
have multiple BCG immunisations, potentially increasing the
magnitude of TST responses. In addition, the measurement of
erythema in defining a positive TST is unique to Japan and
questions the applicability of these findings in countries where the
measurement of induration is standard, despite limited evidence
that there is good correlation between erythema and induration
[32]. Therefore, before this approach can be considered safe,
further, larger studies with longer follow-up are needed to
Figure 3. Relationship between results of QuantiFERON-TB
gold In Tube and T-SPOT.TB assays and TST induration
diameter in the 46 children with a positive tuberculin skin
test (38 with TST-defined latent TB infection and 8 with TB
disease). The broken line indicates a TST induration of 15 mm.
QFT=QuantiFERON-TB gold In Tube, T-Sp=T-SPOT.TB assays, Inde-
t=Indeterminate, TST=tuberculin skin test.
doi:10.1371/journal.pone.0002624.g003
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IGRA negative results and their risk of developing TB disease.
Despite this, the UK National Institute for Clinical Excellence
guidelines for the management of latent TB infection already
recommend withholding preventive treatment in children over two
years of age with a positive TST in whom the result of an IGRA is
negative [33].
The higher rate of indeterminate results in the T-SPOT.TB
assay compared with QFT-IT was attributable to a number of
factors. The T-SPOT.TB is operationally more complex than the
QFT-IT and 9 of the 14 indeterminate T-SPOT.TB results were
attributable to potential laboratory error. The laboratory scientist
undertaking the T-SPOT.TB assay underwent specific training
prior to the study but given the relative complexity of the assay
and the number of processing steps, the chance of a laboratory
error occurring seems to be higher for the T-SPOT.TB assay. The
indeterminate results potentially attributable to laboratory error
were included in our analysis as they reflect real world practice.
However, indeterminate results have been reported less frequently
in the T-SPOT.TB assay than the QFT-IT assay in other studies
[34]. The proportion of indeterminate QFT-IT assays was
significantly less than the 17% reported in our previous study
(p,0.001), the majority of which were due to a high nil control
response [14,35]. In the present study only one assay had a high
nil control response as defined by the manufacturer’s latest
guidelines for test interpretation that allow a significantly higher
background (nil control) response of up to 8 IU/ml. In our current
study, 14% of children had a background IFN-c response $1 IU/
ml and 6% had a background $2 IU/mL. Several other studies
have reported assays with high nil control responses [19,36]. We
have previously highlighted our concern about the validity of
reporting assays with background levels $2 IU/mL [35]. For the
T-SPOT.TB assay, four had background nil control responses
$40 SFCs/10
6. The cause of high nil control responses in IGRA
warrants further investigation.
In conclusion we have shown high agreement between QFT-IT
and T-SPOT.TB in children. Discordant results between TST and
IGRAs are common (most often TST positive, IGRA negative)
and highlight the need for further longitudinal studies to determine
the negative predictive value of IGRAs and the validity of current
recommendations for the investigation and treatment of latent TB
infection in children.
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